September 16, 2024

Michael Zuehlke
Vice President of Finance and Corporate Controller
Zomedica Corp.
100 Phoenix Drive, Suite 125
Ann Arbor, Michigan 48108

       Re: Zomedica Corp.
           Form 10-K for Fiscal Year Ended December 31, 2023
           Form 10-Q for Quarterly Period Ended June 30, 2024
           Form 8-K Filed August 14, 2024
           File No. 001-38298
Dear Michael Zuehlke:

       We have limited our review of your filings to the financial statements
and related
disclosures and have the following comments.

       Please respond to this letter within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe a
comment applies to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to this letter, we may have additional
comments.

Form 10-Q for the Quarterly Period Ended June 30, 2024
Consolidated Statements of Operations and Comprehensive Loss for the Three and
Six Months
Ended June 30, 2024 and 2023, page 4

1.     In future filings, please present the basic and diluted loss per share
to the nearest whole
       cent so as not to imply more precision than exists in this calculation.
Form 8-K Filed August 14, 2024
Exhibt 99.1
Non-GAAP Measures, page 7

2.     We note your non-GAAP reconciliation table gives the appearance of a
full non-GAAP
       income statement. Please note that the presentation of a full non-GAAP
income statement,
       or a presentation that gives the appearance of one, may place undue
prominence on the
       non-GAAP information and give the impression that the non-GAAP income
       statement represents a comprehensive basis of accounting. Please remove
this
 September 16, 2024
Page 2

       presentation in your future filings. To the extent you wish to present
any of the non-
       GAAP measures, you could present a separate reconciliation for each
non-GAAP measure
       and provide all the disclosures required by Item 10(e)(1)(i) of
Regulation S-K including
       quantification and description of each adjustment individually. Refer to
Question
       102.10(a) and (c) of the C&DIs for Non-GAAP Financial Measures.
       In closing, we remind you that the company and its management are
responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review,
comments, action or
absence of action by the staff.

       Please contact Lynn Dicker at 202-551-3616 or Gary Newberry at
202-551-3761 with
any questions.



                                                          Sincerely,

                                                          Division of
Corporation Finance
                                                          Office of Life
Sciences